Transition state analogue inhibitors of N-ribosyltransferases: new drugs by targeting nucleoside processing enzymes.

Gary B. Evans, Richard H. Furneaux, Peter M. Kelly, Vern L. Schramm, Peter C. Tyler

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

The characterization of the transition state structure of a number of N-ribosyltransferases has enabled the design and synthesis of some extremely powerful inhibitors of these enzymes. We have three generations of inhibitors for some nucleoside processing enzymes which are therapeutic targets, and the potency of these compounds confers special advantages in their development as new drugs against cancer, autoimmune diseases, microbial infections and malaria.

Original languageEnglish (US)
Pages (from-to)63-64
Number of pages2
JournalNucleic acids symposium series (2004)
Issue number51
DOIs
StatePublished - 2007
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Transition state analogue inhibitors of N-ribosyltransferases: new drugs by targeting nucleoside processing enzymes.'. Together they form a unique fingerprint.

Cite this